Cocrystal Pharma, Inc.

NasdaqCM:COCP Stock Report

Market Cap: US$23.9m

Cocrystal Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

James Sapirstein

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure14yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

Analysis Article • Apr 04

We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Oct 18

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 11

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma (NASDAQ:COCP) on Tuesday said it had selected its antiviral drug candidate CDI-988 for clinical development as an oral treatment for COVID-19. Shares of the micro-cap clinical-stage biotech fell 7.2% to $2.55 in premarket trading. CDI-988 targets a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral replication, COCP said in a statement. Once investigational new drug application-enabling toxicology studies for CDI-988 are completed, the company plans to file for regulatory approval to begin a human trial in Australia in Q1 2023.
Seeking Alpha • Aug 15

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma press release (NASDAQ:COCP): Q2 GAAP EPS of -$0.25 misses by $0.21. The company reported unrestricted cash of $51M as of June 30, 2022 compared with $58.7M as of Dec. 31, 2021. Net cash used in operating activities for the first half of 2022 was $7.6M. The company reported working capital of $48.8M as of Jun. 30, 2022.
Analysis Article • Aug 14

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 08

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma (NASDAQ:COCP) said it has engaged Open Orphan's (OTCPK:OPORF) unit hVIVO to conduct a phase 2a trial of its oral antiviral CC-42344 to treat pandemic and seasonal influenza A, in the U.K. The trial is expected to begin in H2 2023, pending regulatory approval in the U.K. "We are highly encouraged by the Phase 1 healthy volunteer trial results received so far and are committed to rapidly advancing this program into a human challenge Phase 2a trial in influenza A-infected subjects," said Cocrystal's  President and Co-Interim CEO Sam Lee. Cocrystal is conducting a phase 1 trial of CC-42344 in healthy people in Australia, with full study results expected in 2022.
Analysis Article • Mar 19

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 06

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 05

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 13

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. ( NASDAQ:COCP ) shareholders might be concerned after seeing the share price drop 25% in the...
Analysis Article • Jan 24

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

The big shareholder groups in Cocrystal Pharma, Inc. ( NASDAQ:COCP ) have power over the company. Insiders often own a...
Analysis Article • Dec 20

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. By way of example...

CEO

James Sapirstein (65 yo)

less than a year
Tenure

Mr. James R. Sapirstein is Chief Executive Officer of Cocrystal Pharma, Inc. from June 3, 2026. He is currently the Chairman and Chief Executive Officer of 8 Prime Biosciences and has been an Independent D...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Kornberg
Co-Founder6.4yrsUS$100.00k0.21%
$ 49.3k
Sam Lee
Chief Scientific Officer18.7yrsUS$248.67k0.19%
$ 45.1k
James Martin
CFO & Corporate Secretary9.3yrsUS$265.00k0.23%
$ 54.8k
James Sapirstein
Chief Executive Officerless than a yearno datano data
14.0yrs
Average Tenure
65.5yo
Average Age

Experienced Management: COCP's management team is seasoned and experienced (14 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Kornberg
Co-Founder6.4yrsUS$100.00k0.21%
$ 49.3k
Fred Hassan
Independent Director3.4yrsno data7.18%
$ 1.7m
Richard Pfenniger
Independent Director5.3yrsno data0.16%
$ 38.9k
Phillip Frost
Independent Director12.7yrsno data10.45%
$ 2.5m
Steven Rubin
Independent Vice Chairman12.7yrsno data13.81%
$ 3.3m
Michael Levitt
Member of Scientific Advisory Boardno datano datano data
Carol Brosgart
Directorless than a yearno datano data
Gary Schoolnik
Member of Scientific Advisory Boardno datano datano data
Roland Strong
Member of Scientific Advisory Boardno datano datano data
Christophe Verlinde
Member of Scientific Advisory Boardno datano datano data
Baek Kim
Member of Scientific Advisory Boardno datano datano data
5.9yrs
Average Tenure
79yo
Average Age

Experienced Board: COCP's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 01:41
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cocrystal Pharma, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.
David BautzZacks Small-Cap Research